- Home
- HYFM vs ATHA Comparison
HYFM vs ATHA Comparison
Compare HYFM & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYFM
- ATHA
- Stock Information
- Founded
- HYFM 1977
- ATHA 2011
- Country
- HYFM United States
- ATHA United States
- Employees
- HYFM N/A
- ATHA N/A
- Industry
- HYFM Industrial Machinery/Components
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- HYFM Industrials
- ATHA Health Care
- Exchange
- HYFM Nasdaq
- ATHA Nasdaq
- Market Cap
- HYFM 17.3M
- ATHA 14.8M
- IPO Year
- HYFM 2020
- ATHA 2020
- Fundamental
- Price
- HYFM $3.25
- ATHA $0.36
- Analyst Decision
- HYFM
- ATHA Hold
- Analyst Count
- HYFM 0
- ATHA 3
- Target Price
- HYFM N/A
- ATHA $0.50
- AVG Volume (30 Days)
- HYFM 22.2K
- ATHA 159.8K
- Earning Date
- HYFM 11-06-2025
- ATHA 11-06-2025
- Dividend Yield
- HYFM N/A
- ATHA N/A
- EPS Growth
- HYFM N/A
- ATHA N/A
- EPS
- HYFM N/A
- ATHA N/A
- Revenue
- HYFM $161,102,000.00
- ATHA N/A
- Revenue This Year
- HYFM $5.45
- ATHA N/A
- Revenue Next Year
- HYFM $5.33
- ATHA N/A
- P/E Ratio
- HYFM N/A
- ATHA N/A
- Revenue Growth
- HYFM N/A
- ATHA N/A
- 52 Week Low
- HYFM $1.50
- ATHA $0.22
- 52 Week High
- HYFM $8.55
- ATHA $0.83
- Technical
- Relative Strength Index (RSI)
- HYFM 32.58
- ATHA 36.59
- Support Level
- HYFM $2.65
- ATHA $0.35
- Resistance Level
- HYFM $3.30
- ATHA $0.40
- Average True Range (ATR)
- HYFM 0.31
- ATHA 0.02
- MACD
- HYFM -0.13
- ATHA -0.00
- Stochastic Oscillator
- HYFM 28.44
- ATHA 11.86
About HYFM Hydrofarm Holdings Group Inc.
Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.